Cohance Lifesciences' Q1 FY 2025-26 Quarter Results

Result Summary

• Cohance Lifesciences Ltd reported a 108.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 126.4%.
• Its expenses for the quarter were up by 147.4% QoQ and 197.2% YoY.
• The net profit decreased 13.1% QoQ and decreased 23.6% YoY.
• The earnings per share (EPS) of Cohance Lifesciences Ltd stood at 1.3 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Cohance Lifesciences Ltd is a company engaged in the life sciences industry, which typically encompasses the research, development, and manufacturing of products related to pharmaceuticals, biotechnology, and healthcare. Specific details about the company's main products or recent major developments are not available within the provided data. As a player in the life sciences sector, the company is likely involved in developing medical products or technologies aimed at improving health outcomes. Given the sector's dynamic nature, Cohance Lifesciences might benefit from advances in medical research, regulatory changes, and market demand for innovative healthcare solutions.

Revenue

During the first quarter of fiscal year 2026 (Q1FY26), Cohance Lifesciences Ltd reported a total income of ₹563.48 crores. This represents a significant increase of 108.7% compared to the previous quarter (Q4FY25), where total income was ₹269.98 crores. On a year-over-year basis, from Q1FY25, total income grew by 126.4%, with the previous year's first-quarter income standing at ₹248.85 crores. These figures suggest considerable growth in revenue streams over both the quarterly and yearly periods. The substantial rise in total income may reflect increased sales, expansion into new markets, or successful product launches during the period.

Profitability

In terms of profitability, Cohance Lifesciences Ltd recorded a profit before tax of ₹62.76 crores in Q1FY26, which is a decrease of 11.4% compared to ₹70.85 crores in Q4FY25. Year-over-year, profit before tax fell by 24.5% from ₹83.09 crores in Q1FY25. The tax expense for Q1FY26 was ₹16.36 crores, representing a decline of 6.4% from the previous quarter's tax of ₹17.48 crores and a 26.7% decrease from ₹22.32 crores in the same quarter last year. After accounting for tax, the profit after tax for Q1FY26 was ₹46.40 crores, down by 13.1% from ₹53.37 crores in Q4FY25 and by 23.6% from ₹60.77 crores in Q1FY25. The earnings per share (EPS) also followed a downward trajectory, decreasing by 38.1% quarter-over-quarter from ₹2.10 to ₹1.30, and by 45.8% year-over-year from ₹2.40.

Operating Metrics

Operating expenses for Cohance Lifesciences Ltd in Q1FY26 stood at ₹492.62 crores, rising sharply by 147.4% from ₹199.14 crores in Q4FY25. Year-over-year, operating expenses increased by 197.2% from ₹165.76 crores in Q1FY25. The substantial rise in expenses may affect the company's operating efficiency and margins. Despite the increase in total income, the growth in expenses has impacted overall profitability. The changes in earnings per share, along with the variations in profit metrics, highlight the influence of operating costs on the company's financial performance. Key financial ratios such as the P/E ratio, debt-to-equity ratio, and current ratio are not provided in the data, thus limiting further financial analysis.